The company's principal activity is to conduct research, development and test, as well as manufacture, market and distribute a hemoglobin-based blood substitute product. The company's product, polyheme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. It uses a proprietary process of separation, filtration and chemical modification to produce polyheme. Clinical trials of polyheme have been conducted at multiple locations in the United States. The company has entered into licensing agreements with pharmacia corporation and hemocare ltd. To develop, manufacture and distribute polyheme in certain European, Middle Eastern and african countries. The company is in development stage.
